|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
US8263746B2
(en)
|
2004-02-06 |
2012-09-11 |
Morphosys Ag |
Anti-CD38 human antibodies and uses thereof
|
|
US20050255120A1
(en)
*
|
2004-05-12 |
2005-11-17 |
Simon Michael R |
Composition and method for introduction of DNA directed RNA interference sequences into targeted cells and tissues
|
|
US20110117088A1
(en)
*
|
2004-05-12 |
2011-05-19 |
Simon Michael R |
Composition and method for introduction of rna interference sequences into targeted cells and tissues
|
|
US20050260214A1
(en)
*
|
2004-05-12 |
2005-11-24 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
|
US20060030003A1
(en)
*
|
2004-05-12 |
2006-02-09 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
|
US20110110937A1
(en)
*
|
2004-05-12 |
2011-05-12 |
Simon Michael R |
Composition and method for introduction of rna interference sequences into targeted cells and tissues
|
|
EP2567976B1
(en)
|
2005-03-23 |
2017-07-19 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
|
TW200745162A
(en)
*
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
EP2860192B1
(en)
|
2005-10-12 |
2017-09-27 |
MorphoSys AG |
Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
|
|
US20070106233A1
(en)
*
|
2005-10-20 |
2007-05-10 |
Percutaneous Systems, Inc. |
Systems and methods for dilating and accessing body lumens
|
|
US20100267145A1
(en)
*
|
2006-06-05 |
2010-10-21 |
Hiroshima University |
Immunocompetent cell having anti-cd38 antibody on its cell surface
|
|
US20100150941A1
(en)
*
|
2006-09-13 |
2010-06-17 |
Dso National Laboratories |
Hemagglutinin antibody and uses thereof
|
|
EP3569245A1
(en)
*
|
2006-09-26 |
2019-11-20 |
Genmab A/S |
Combination treatment of cd38-expressing tumors
|
|
EP2191841A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
EP2191842A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
|
EP2191843A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
|
EP2191840A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
DK2580243T3
(da)
|
2010-06-09 |
2020-01-13 |
Genmab As |
Antibodies against human cd38
|
|
KR101930179B1
(ko)
*
|
2010-08-27 |
2018-12-17 |
길리아드 바이오로직스, 인크. |
매트릭스 메탈로프로테이나제 ９에 대한 항체
|
|
SI2621531T1
(sl)
|
2010-09-27 |
2017-06-30 |
Morphosys Ag |
Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
NZ629178A
(en)
|
2012-02-29 |
2016-09-30 |
Gilead Biologics Inc |
Antibodies to matrix metalloproteinase 9
|
|
GB201216002D0
(en)
*
|
2012-09-07 |
2012-10-24 |
Deutsches Rheuma Forschungszentrum Berlin Drfz |
Compositions adn methods
|
|
JP6426093B2
(ja)
|
2012-09-25 |
2018-11-28 |
モルフォシス・アーゲー |
組み合わせ及びその使用
|
|
ES2621377T3
(es)
|
2012-11-05 |
2017-07-03 |
Morphosys Ag |
Anticuerpo marcado radiactivamente y usos del mismo
|
|
CN111909278B
(zh)
|
2014-01-27 |
2024-04-09 |
分子模板公司 |
Mhc i类表位递送多肽
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
ES2919749T3
(es)
|
2014-06-11 |
2022-07-28 |
Molecular Templates Inc |
Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
|
|
MX386886B
(es)
|
2014-09-09 |
2025-03-12 |
Janssen Biotech Inc |
Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
|
|
AU2015358615B2
(en)
|
2014-12-04 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute myeloid leukemia
|
|
MX2017010072A
(es)
|
2015-02-05 |
2017-11-09 |
Molecular Templates Inc |
Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
|
|
PT3294769T
(pt)
|
2015-05-13 |
2021-04-13 |
Morphosys Ag |
Tratamento para mieloma múltiplo (mm)
|
|
MX389805B
(es)
*
|
2015-05-20 |
2025-03-11 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
|
|
AU2016271124C1
(en)
|
2015-05-30 |
2020-05-14 |
Molecular Templates, Inc. |
De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
AU2016282674B2
(en)
|
2015-06-22 |
2022-01-13 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
DK3827845T3
(da)
|
2015-11-03 |
2022-05-23 |
Janssen Biotech Inc |
Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
|
|
MA43365A
(fr)
|
2015-12-01 |
2018-10-10 |
Genmab Bv |
Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
|
|
WO2017149122A1
(en)
|
2016-03-04 |
2017-09-08 |
Morphosys Ag |
Clinical assessment of m-protein response in multiple myeloma
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
WO2018106895A1
(en)
|
2016-12-07 |
2018-06-14 |
Molecular Templates, Inc. |
Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
|
|
EP3573648B1
(en)
|
2017-01-25 |
2023-11-22 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
JP2021502961A
(ja)
|
2017-10-31 |
2021-02-04 |
ヤンセン バイオテツク，インコーポレーテツド |
高リスク多発性骨髄腫の治療方法
|
|
US20230158070A1
(en)
|
2018-01-30 |
2023-05-25 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
AU2019257343A1
(en)
|
2018-04-17 |
2020-09-10 |
Molecular Templates, Inc. |
HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
|
|
CN109265551B
(zh)
*
|
2018-09-25 |
2020-09-15 |
华东师范大学 |
Cd38抗体、嵌合抗原受体和药物
|
|
CN113194925B
(zh)
|
2018-12-14 |
2025-03-07 |
莫佛塞斯公司 |
抗体制剂
|
|
EP3938394A1
(en)
|
2019-03-15 |
2022-01-19 |
MorphoSys AG |
Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
|
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えａｄ３５ベクター及び関連遺伝子治療改善
|
|
WO2022152823A1
(en)
|
2021-01-14 |
2022-07-21 |
Morphosys Ag |
Anti-cd38 antibodies and their uses
|
|
TW202302642A
(zh)
|
2021-03-01 |
2023-01-16 |
德商莫菲西斯公司 |
用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
|
|
TW202321303A
(zh)
|
2021-07-19 |
2023-06-01 |
德商莫菲西斯公司 |
抗pla2r自體抗體媒介膜性腎病變之治療
|